Form 4: Aurinia Pharmaceuticals Director Karen L. Smith Reports Stock Transactions
SEC Form 4 Filing
Director Karen L. Smith of Aurinia Pharmaceuticals reported the acquisition of 17,913 shares through vested restricted stock units and the sale of 5,241 shares to cover tax obligations.
Summary
- Karen L. Smith, a director at Aurinia Pharmaceuticals, reported transactions involving the company's common stock.
- On November 8, 2024, Ms. Smith acquired 17,913 shares through the vesting of restricted stock units (RSUs).
- These RSUs represent a contingent right to receive one share of Aurinia's common stock each.
- On November 11, 2024, Ms. Smith sold 5,241 shares at a weighted average price of $8.43 per share to cover tax withholding obligations related to the vesting of the RSUs.
- The sale price ranged from $8.37 to $8.47 per share.
- Following these transactions, Ms. Smith directly owns 12,672 shares of Aurinia Pharmaceuticals.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing of insider transactions, which is neither positive nor negative for the company's outlook.
Industry Context
This is a routine filing related to insider transactions, which is common for publicly traded companies. It provides transparency into the trading activities of company directors.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
- The transactions reported are typical for directors who receive stock-based compensation, such as restricted stock units.
- The sale of shares to cover tax obligations is a common occurrence when RSUs vest.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are routine insider transactions.
- The sale of shares by a director may be perceived as slightly negative, but it is a common practice to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 11/08/2024 | Restricted stock units vested, resulting in the acquisition of 17,913 shares. |
| 11/11/2024 | 5,241 shares were sold to cover tax obligations at an average price of $8.43. |
| 11/12/2024 | Date of signature for the Form 4 filing. |
Keywords
Aurinia Pharmaceuticals, insider trading, Form 4, stock transaction, restricted stock units, Karen L. Smith, share sale, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.